Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst
Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind.
Overview
Novo Nordisk (NYSE: NVO) was the first company to produce a GLP-1 weight-loss shot. Technically, the shot was meant for diabetics, but its ability to help people lose weight hit home with more than just diabetics. The drugmaker couldn't keep up with demand, creating an opportunity for Eli Lilly (NYSE: LLY), which was second to market with GLP-1 shots. When Eli Lilly's drugs appeared to be more effective, it quickly took the lead in the new weight-loss niche. The two companies are competing for market share again, but this time, Novo Nordisk could have the edge. Here's why.
Novo Nordisk's GLP-1 drug is known as either Wegovy or Ozempic. They are the same compound, just targeted at different things: one is meant for diabetics, and the other for those looking to lose weight. Eli Lilly's GLP-1 shot is broken up similarly, with the brand names Mounjaro and Zepbound.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
- SpaceX vs. Apple: Wall Street Sees Strong Upside for One of These Stocks and Remains Neutral On the Other
- Stock futures fall as investors weigh AI safety concerns, oil gains: Live updates
- Berkshire Hathaway Stock Is Trailing the S&P 500 by About 10 Points This Year. History Says That Usually Doesn't Last.